BG62952B1 - Модафинил с определен размер на частиците - Google Patents

Модафинил с определен размер на частиците Download PDF

Info

Publication number
BG62952B1
BG62952B1 BG101389A BG10138997A BG62952B1 BG 62952 B1 BG62952 B1 BG 62952B1 BG 101389 A BG101389 A BG 101389A BG 10138997 A BG10138997 A BG 10138997A BG 62952 B1 BG62952 B1 BG 62952B1
Authority
BG
Bulgaria
Prior art keywords
modafinil
particles
diameter
median
particle size
Prior art date
Application number
BG101389A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101389A (en
Inventor
Peter Grebow
Vincent Corvari
David Stong
Original Assignee
Cephalon,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23240954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62952(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon,Inc. filed Critical Cephalon,Inc.
Publication of BG101389A publication Critical patent/BG101389A/xx
Publication of BG62952B1 publication Critical patent/BG62952B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Paints Or Removers (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Packaging For Recording Disks (AREA)
  • Laminated Bodies (AREA)
  • Slot Machines And Peripheral Devices (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG101389A 1994-10-06 1997-04-04 Модафинил с определен размер на частиците BG62952B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/319,124 US5618845A (en) 1994-10-06 1994-10-06 Acetamide derivative having defined particle size
PCT/US1995/012944 WO1996011001A1 (en) 1994-10-06 1995-10-04 Modafinil having defined particle size

Publications (2)

Publication Number Publication Date
BG101389A BG101389A (en) 1997-12-30
BG62952B1 true BG62952B1 (bg) 2000-12-29

Family

ID=23240954

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101389A BG62952B1 (bg) 1994-10-06 1997-04-04 Модафинил с определен размер на частиците

Country Status (34)

Country Link
US (2) US5618845A (pl)
EP (3) EP0966962B1 (pl)
JP (1) JP2915146B2 (pl)
KR (1) KR100249360B1 (pl)
AT (3) ATE188607T1 (pl)
AU (1) AU703087B2 (pl)
BG (1) BG62952B1 (pl)
BR (1) BR9509257A (pl)
CA (2) CA2201967C (pl)
CZ (1) CZ291700B6 (pl)
DE (3) DE69520161T2 (pl)
DK (3) DK0966962T3 (pl)
EE (1) EE9700082A (pl)
ES (3) ES2156457T3 (pl)
FI (1) FI121454B (pl)
GB (1) GB2293103B (pl)
GR (2) GR3033152T3 (pl)
HK (3) HK1003561A1 (pl)
HU (1) HU226411B1 (pl)
IS (1) IS1987B (pl)
LT (1) LT4303B (pl)
LV (1) LV11852B (pl)
MD (1) MD970143A (pl)
MX (1) MX9602176A (pl)
NO (1) NO318818B1 (pl)
NZ (1) NZ295869A (pl)
PL (1) PL181523B1 (pl)
PT (3) PT966962E (pl)
RO (1) RO118928B1 (pl)
RU (1) RU2287987C2 (pl)
SI (1) SI9520106B (pl)
SK (1) SK283632B6 (pl)
UA (1) UA42023C2 (pl)
WO (1) WO1996011001A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71629C2 (en) * 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
CA2416792C (en) * 2000-07-27 2010-02-09 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same
WO2002030414A1 (en) * 2000-10-11 2002-04-18 Cephalon, Inc. Compositions comprising modafinil compounds
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
IL155322A0 (en) * 2000-10-11 2003-11-23 Cephalon Inc Compositions comprising modafinil compounds
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7576133B2 (en) 2002-03-11 2009-08-18 Carl Henry Lawyer Methods and compositions for nasal administration of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
AU2003249105A1 (en) * 2002-07-08 2004-01-23 Ranbaxy Laboratories Limited Processes for the preparation of oral dosage formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CN1684666A (zh) * 2002-07-25 2005-10-19 兰贝克赛实验室有限公司 制备莫达非尼口服剂型的方法
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
CA2420180A1 (en) * 2003-02-28 2004-08-28 Bernard Charles Sherman Tablets comprising modafinil
CA2519117C (en) * 2003-03-17 2010-03-02 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ES2330321T3 (es) * 2003-05-16 2009-12-09 Cephalon France Procedimiento de sintesis de modafinilo.
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
AU2006272874B2 (en) * 2005-07-21 2010-03-11 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
CA2628716C (en) * 2005-11-10 2016-09-27 Alphapharm Pty Ltd Process to control particle size
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
US7884135B2 (en) * 2006-08-14 2011-02-08 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
WO2008074097A1 (en) 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
EP2318350A4 (en) * 2008-07-25 2012-11-28 Alphapharm Pty Ltd ATOVAQUONE WITH PARTICLE DIAMETER (D90) VARIANT FROM MORE THAN 3 muM TO ABOUT 10 muM
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
FR2987265B1 (fr) * 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application
FR2987267B1 (fr) * 2012-02-28 2015-01-16 Debregeas Et Associes Pharma Application du modafinil dans le traitement de substitution des cacainomanes
FR2987266B1 (fr) * 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
US4600614A (en) * 1983-09-12 1986-07-15 The Dow Chemical Company High-frequency heatable plastics
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
FR2702968B1 (fr) * 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
ATE222993T1 (de) 1993-04-05 2002-09-15 Sds Pty Ltd Schlagbohrhammer
FR2706767B1 (pl) * 1993-06-22 1995-09-08 Lafon Labor
FR2708201B1 (fr) * 1993-06-30 1995-10-20 Lafon Labor Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
US5493146A (en) 1994-07-14 1996-02-20 Vlsi Technology, Inc. Anti-fuse structure for reducing contamination of the anti-fuse material

Also Published As

Publication number Publication date
NO971541L (no) 1997-06-04
DE69520161D1 (de) 2001-03-29
AU703087B2 (en) 1999-03-18
KR100249360B1 (ko) 2000-04-01
ES2142499T3 (es) 2000-04-16
LV11852B (en) 1998-03-20
ES2156457T3 (es) 2001-06-16
RO118928B1 (ro) 2004-01-30
ATE188607T1 (de) 2000-01-15
RU2287987C2 (ru) 2006-11-27
EP1088549A1 (en) 2001-04-04
JPH09511754A (ja) 1997-11-25
FI121454B (fi) 2010-11-30
JP2915146B2 (ja) 1999-07-05
BR9509257A (pt) 1998-07-07
SI9520106A (sl) 1998-02-28
GR3035451T3 (en) 2001-05-31
SK283632B6 (sk) 2003-11-04
NO318818B1 (no) 2005-05-09
EP0966962B1 (en) 2001-02-21
HK1034676A1 (en) 2001-11-02
CA2201967C (en) 2002-12-10
MD970143A (ro) 1998-12-31
CZ291700B6 (cs) 2003-05-14
MX9602176A (es) 1997-05-31
DE69535786D1 (de) 2008-08-21
LV11852A (lv) 1997-10-20
HK1003561A1 (en) 1998-10-30
DE69514497T2 (de) 2000-08-10
PT966962E (pt) 2001-06-29
US5618845A (en) 1997-04-08
FI971417A (fi) 1997-04-04
EP0966962A1 (en) 1999-12-29
IS1987B (is) 2005-02-15
HU226411B1 (en) 2008-11-28
PT731698E (pt) 2000-05-31
AU3951495A (en) 1996-05-02
ATE199216T1 (de) 2001-03-15
GR3033152T3 (en) 2000-08-31
NO971541D0 (no) 1997-04-04
SK44597A3 (en) 1997-09-10
PL181523B1 (en) 2001-08-31
EP0731698A1 (en) 1996-09-18
DK1088549T3 (da) 2008-11-17
CA2201967A1 (en) 1996-04-18
DE69520161T2 (de) 2001-08-02
SI9520106B (sl) 2003-12-31
WO1996011001A1 (en) 1996-04-18
BG101389A (en) 1997-12-30
UA42023C2 (uk) 2001-10-15
FI971417A0 (fi) 1997-04-04
DE69514497D1 (de) 2000-02-17
HK1024625A1 (en) 2000-10-20
PT1088549E (pt) 2008-09-23
EP1088549B1 (en) 2008-07-09
GB9524328D0 (en) 1996-01-31
USRE37516E1 (en) 2002-01-15
PL319480A1 (en) 1997-08-04
HUT77778A (hu) 1998-08-28
DK0966962T3 (da) 2001-03-19
EE9700082A (et) 1997-10-15
GB2293103B (en) 1997-05-07
CA2382275A1 (en) 1996-04-18
LT97060A (en) 1997-10-27
ATE400260T1 (de) 2008-07-15
DK0731698T3 (da) 2000-05-08
ES2308960T3 (es) 2008-12-16
EP0731698B1 (en) 2000-01-12
GB2293103A (en) 1996-03-20
CA2382275C (en) 2003-12-16
NZ295869A (en) 1998-02-26
LT4303B (lt) 1998-03-25
CZ103297A3 (en) 1997-09-17
IS4451A (is) 1997-03-24

Similar Documents

Publication Publication Date Title
BG62952B1 (bg) Модафинил с определен размер на частиците
ES2285189T3 (es) Composiciones farmcaeuticas de modafinilo.
BRPI1014278B1 (pt) método para produzir uma forma de dosagem compreendendo metaxolona, forma de dosagem, composição farmacêutica compreendendo a referida forma de dosagem e uso da mesma
BR112015025058B1 (pt) Composição farmacêutica do tipo matriz contendo lacosamida
RU2171674C2 (ru) Модафинил с определенным размером частиц
CN114796133A (zh) 一种注射用药物制剂及其制备方法
AU729586B2 (en) Modafinil having defined particle size
Parashar et al. Formulation And Characterization Of Combination Drug Microspheres For Diabetes Mellitus Management
Jaiswal et al. Formulation, Evaluation and Optimization of Solid Dispersion Tablet of Combination of Repaglinide and Metformin Hydrochloride Using Face Centered Central Composite Design
Hiremath Formulation and Evaluation of Microcapsules for Controlled Release of Anti Diabetic Drug by Ionotropic Gelation Technique